Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wayne Lee

Plastic Surgery Brandon, FL Medical Doctor

NPI 1598833543 CMS profile 72471

1020 E Brandon Blvd Ste 101, Brandon, FL 33511

Open in the dashboard

General payments

$7,060

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wayne Lee of Brandon, FL is reported in the CMS Open Payments database as having received $7,060 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $361 19
2024 General $665 22
2023 General $1,774 28
2022 General $1,217 29
2021 General $259 14
2020 General $2,562 22
2019 General $222 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wayne Lee
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Wayne Lee were reported at $361. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Wayne Lee Plastic Surgery median Middle half National median
2019 $222 $371 $122–$1,483 $163
2020 $2,562 $158 $52–$438 $114
2021 $259 $249 $87–$752 $132
2022 $1,217 $274 $102–$793 $149
2023 $1,774 $299 $113–$891 $160
2024 $665 $361 $124–$1,062 $164
2025 $361 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,310 58 payments
  2. Allergan Inc. $1,608 62 payments
  3. AcelRx Pharmaceuticals, Inc. $1,349 8 payments
  4. Acell, Inc. $1,052 3 payments
  5. Smith+Nephew, Inc. $225 7 payments
  6. TELA Bio, Inc. $188 2 payments
  7. Baxter Healthcare $124 1 payment
  8. Mentor Worldwide LLC $81 2 payments
  9. Vertical Pharmaceuticals, LLC $58 3 payments
  10. MIMEDX Group, Inc. $33 2 payments
  11. Other $32 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,562 142 payments
  2. Consulting Fee $1,200 1 payment
  3. Travel and Lodging $1,195 3 payments
  4. Education $1,052 3 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $51 1 payment
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $1,681 27 payments
  2. DSUVIA $1,349 8 payments
  3. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $1,242 9 payments
  4. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $1,062 31 payments
  5. ALLODERM $533 30 payments
  6. NATRELLE $280 18 payments
  7. OviTex 2S $171 1 payment
  8. PICO $144 3 payments
  9. ARTISS $124 1 payment
  10. MENTOR MemoryGel Resterilizable Gel Sizer $81 2 payments
  11. Other $301 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

179

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$14,462

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

30.2%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 13 $6,974
Eliquis Apixaban Brand 13 $6,783
Cephalexin Generic 15 $150
Montelukast Sodium Generic 24 $127
Ondansetron Odt Ondansetron Brand 15 $109
Mupirocin Generic 14 $85
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $73
Losartan Potassium Generic 13 $64
Metoprolol Succinate Generic 12 $34
Omeprazole Generic 11 $27

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record